Search research articles
Contact Us
Filters
Showing results (61-70 of 126) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer
Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
The Journal of Clinical Investigation
|
August 30, 2008
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo, Li Ma, Julie Teruya-Feldstein, et al.
JAMA Oncology
|
June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Ryan L Powles, David Redmond, Christos Sotiriou, et al.
JAMA Oncology
|
July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado, Carsten Denkert, Christine Campbell, et al.
Cardiovascular Toxicology
|
December 10, 2014
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Richard J Kovacs, Giuliana Maldonado, Analia Azaro, et al.
Cancer Research
|
September 28, 2017
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Rona Yaeger, Zhan Yao, David M Hyman, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasis
Jose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy
Cristina Saura, Johanna Bendell, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2012
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
Andres Cervantes, Elena Elez, Desamparados Roda, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 126) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer
Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, et al.
The Journal of Clinical Investigation
|
August 30, 2008
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo, Li Ma, Julie Teruya-Feldstein, et al.
JAMA Oncology
|
June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Ryan L Powles, David Redmond, Christos Sotiriou, et al.
JAMA Oncology
|
July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado, Carsten Denkert, Christine Campbell, et al.
Cardiovascular Toxicology
|
December 10, 2014
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Richard J Kovacs, Giuliana Maldonado, Analia Azaro, et al.
Cancer Research
|
September 28, 2017
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Rona Yaeger, Zhan Yao, David M Hyman, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasis
Jose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy
Cristina Saura, Johanna Bendell, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2012
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
Andres Cervantes, Elena Elez, Desamparados Roda, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Page
of 13